CA2749947A1 - Methodes de traitement de cancer positif aux recepteurs oestrogeniques par inhibition de la proteine de liaison a la boite x 1 (xbp1) - Google Patents

Methodes de traitement de cancer positif aux recepteurs oestrogeniques par inhibition de la proteine de liaison a la boite x 1 (xbp1) Download PDF

Info

Publication number
CA2749947A1
CA2749947A1 CA2749947A CA2749947A CA2749947A1 CA 2749947 A1 CA2749947 A1 CA 2749947A1 CA 2749947 A CA2749947 A CA 2749947A CA 2749947 A CA2749947 A CA 2749947A CA 2749947 A1 CA2749947 A1 CA 2749947A1
Authority
CA
Canada
Prior art keywords
xbp1
cells
seq
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2749947A
Other languages
English (en)
Inventor
David Kiewlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2749947A1 publication Critical patent/CA2749947A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2749947A 2009-01-30 2010-01-29 Methodes de traitement de cancer positif aux recepteurs oestrogeniques par inhibition de la proteine de liaison a la boite x 1 (xbp1) Abandoned CA2749947A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14851809P 2009-01-30 2009-01-30
US61/148,518 2009-01-30
PCT/US2010/022552 WO2010088498A1 (fr) 2009-01-30 2010-01-29 Méthodes de traitement de cancer positif aux récepteurs oestrogéniques par inhibition de la protéine de liaison à la boîte x 1 (xbp1)

Publications (1)

Publication Number Publication Date
CA2749947A1 true CA2749947A1 (fr) 2010-08-05

Family

ID=42396035

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2749947A Abandoned CA2749947A1 (fr) 2009-01-30 2010-01-29 Methodes de traitement de cancer positif aux recepteurs oestrogeniques par inhibition de la proteine de liaison a la boite x 1 (xbp1)

Country Status (3)

Country Link
EP (1) EP2391372A4 (fr)
CA (1) CA2749947A1 (fr)
WO (1) WO2010088498A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800811C (fr) 2010-05-28 2019-02-26 The Board Of Regents Of The University Of Texas System Composes oligo-benzamide et leur utilisation
WO2012109238A2 (fr) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
GB201109965D0 (en) * 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US20150018406A1 (en) * 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
EP3521431A1 (fr) 2013-09-25 2019-08-07 Cornell University Composés pour induire l'immunité antitumorale et procédés associés
WO2020011909A1 (fr) * 2018-07-11 2020-01-16 Secarna Pharmaceuticals Gmbh & Co. Kg Polymères d'acides nucléiques inhibant l'expression de xbp1
WO2021119561A1 (fr) * 2019-12-12 2021-06-17 University Of Maryland, Baltimore Inhibiteurs de biomarqueurs du cancer et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784883B2 (en) * 1999-12-30 2006-07-20 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
US20030143539A1 (en) * 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
CA2496897C (fr) * 2002-08-30 2012-01-31 President And Fellows Of Harvard College Procedes et compositions permettant la modulation de l'activite xbp-1
CN101965190A (zh) * 2005-04-04 2011-02-02 维里德克斯有限责任公司 乳腺肿瘤的激光显微解剖和微阵列分析揭示雌激素受体相关的基因和途径
WO2007101224A2 (fr) * 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation

Also Published As

Publication number Publication date
EP2391372A1 (fr) 2011-12-07
EP2391372A4 (fr) 2013-07-03
WO2010088498A1 (fr) 2010-08-05

Similar Documents

Publication Publication Date Title
CA2749947A1 (fr) Methodes de traitement de cancer positif aux recepteurs oestrogeniques par inhibition de la proteine de liaison a la boite x 1 (xbp1)
Song et al. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells
Li et al. Dexmedetomidine inhibits inflammatory response and autophagy through the circLrp1b/miR-27a-3p/Dram2 pathway in a rat model of traumatic brain injury
Liu et al. TNF-α/calreticulin dual signaling induced NLRP3 inflammasome activation associated with HuR nucleocytoplasmic shuttling in rheumatoid arthritis
Zhen et al. Downregulating lncRNA NEAT1 induces proliferation and represses apoptosis of ovarian granulosa cells in polycystic ovary syndrome via microRNA-381/IGF1 axis
Priya et al. Specificity protein 4 functionally regulates the transcription of NMDA receptor subunits GluN1, GluN2A, and GluN2B
Liu et al. CircPSMC3 alleviates the symptoms of PCOS by sponging miR‐296‐3p and regulating PTEN expression
Hägerstrand et al. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541
Zhang et al. Tisp40 prevents cardiac ischemia/reperfusion injury through the hexosamine biosynthetic pathway in male mice
US11873494B2 (en) Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
Tao et al. Tripterygium glycoside suppresses epithelial‑to‑mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR/Twist1 pathway
Walker et al. Silencing of insulin receptor substrate–1 increases cell death in retinal Müller cells
Yao et al. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma
US20130333059A1 (en) Hox compositions and methods
Martínez-Moreno et al. Neuroprotection by GH against excitotoxic-induced cell death in retinal ganglion cells
Yang et al. EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells
Yuan et al. RAB5A promotes the formation of filopodia in pancreatic cancer cells via the activation of cdc42 and β1-integrin
Shi et al. Upregulation of CPNE3 suppresses invasion, migration and proliferation of glioblastoma cells through FAK pathway inactivation
Bradley et al. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line
Milton et al. FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas
Li et al. Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling
Imai et al. Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal‐regulated kinase
Ma et al. Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene
Glait et al. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1-and p53-dependent pathways
Jensen et al. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20140129